multiple indications (Crohn's disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis)
Gastroenterology · 2024–2024
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Complex refractory fistulising Crohn disease, severe Crohn disease, moderate to severe ulcerative colitis, moderate to severe hidradenitis suppurativa, and… | Mar 2024 | Recommended with restriction | input received Colitis Australia |
Who spoke
Colitis Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.